^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Pancreatic Cancer
    Drug:glecirasib (JAB-21822) (KRAS G12C inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    PRNewswire
    Title:

    Jacobio Pharma Announces Breakthrough Therapy Designation from China CDE for KRAS G12C Inhibitor Glecirasib for the Treatment of Pancreatic Cancer

    Published date:
    08/07/2023
    Excerpt:
    Jacobio...announced that Jacobio’s in-house KRAS G12C inhibitor glecirasib was granted breakthrough therapy designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the pancreatic cancer patients with a KRAS G12C mutation who have progressed after frontline standard care treatment.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of JAB-21822 in Patients With KRAS p.G12C Mutated Pancreatic Cancer

    Excerpt:
    ...- Histopathologically or cytologically confirmed pancreatic cancer with KRAS p.G12C mutation identified through molecular testing....
    Trial ID:
    NCT06008288